Company Profile
AICON-BIO (Aicon Biotech Inc.)
Founded in 2017 in Oregon, AICON-BIO began with a mission to provide a comprehensive immunology total solution, specializing in microbiology, ELISA, rapid test, and related IVD raw materials. Building on this strong foundation, the company expanded into molecular diagnostics, with a particular focus on women’s molecular testing and animal molecular testing.
In 2021, AICON-BIO entered the field of regenerative biotechnology and cell & gene therapy, specializing in mesenchymal stem cell (MSC) culture technologies. By 2023, the company launched its innovative NeoPL Human Platelet Lysate, a next-generation, serum-free growth supplement designed for advanced cell culture applications along with customized multi-chamber cell culture systems to support biotech research and pharmaceutical development.
Today, AICON-BIO continues to integrate diagnostic innovation with regenerative biotechnology, delivering reliable, high-quality solutions that empower both scientific research and clinical advancement.
Our Commitment
At AICON-BIO, we are driven by a deep passion for science and a commitment to making a meaningful impact on global health. By providing innovative solutions, trusted quality, and exceptional customer support, we help our partners achieve their goals, ultimately contributing to better healthcare outcomes worldwide.
